Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestogen presented as a 52 mg intrauterine system for intrauterine use. It provides long‑acting reversible contraception and prevents pregnancy.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert, a levonorgestrel‑based intrauterine system, is used for hormonal contraception.

- Contraception: provides continuous pregnancy prevention for up to five years. - Management of heavy menstrual bleeding: may reduce the volume and duration of bleeding. - Non‑oral hormonal birth control: offers a progestogen‑only option for women who prefer an intrauterine method.

Levosert may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or spotting. - Menstrual cramps or pelvic discomfort after insertion. - Amenorrhea (absence of periods) after several months. - Vaginal discharge or odor.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Expulsion of the device. - Pelvic inflammatory disease or severe infection. - Allergic reaction to levonorgestrel or device components.

Before using Levosert, clinicians should assess patient suitability and counsel on potential risks.

- Uterine assessment: confirm normal cavity size and shape. - Infection screening: ensure no active pelvic infection. - Contraindications: avoid in women with known hypersensitivity to levonorgestrel. - Insertion technique: performed by trained healthcare professional. - Follow‑up: monitor for signs of expulsion or infection. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levosert can interact with medications that affect hormone metabolism or uterine environment.

Major Interactions (Avoid): - Rifampicin or other strong enzyme inducers: may reduce levonorgestrel efficacy. - Antiepileptic drugs such as carbamazepine or phenytoin: can lower hormone levels. - St John's wort: may diminish contraceptive effect.

Moderate Interactions (Monitor Closely): - Certain antiretrovirals (e.g., efavirenz): may modestly decrease effectiveness. - Antifungal agents like ketoconazole: could increase hormone exposure. - Hormonal therapies (e.g., estrogen patches): assess combined hormonal impact.